Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | PEPD | P12955 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.37 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3706911 | 1.00 | LTA4H (0.48) | LTA4HPOLBFKBP1APARP1ADRA1D | |
| Trifluoroacetic Acid SCHEMBL28510173 | 0.91 | LTA4H (0.43) | LTA4HPOLBFKBP1APARP1ADRA1D | |
| SCHEMBL3315632 | 0.82 | LTA4H (0.47) | LTA4HPOLBFKBP1AADRA1DADRA1A | |
| SCHEMBL25728389 | 0.82 | LTA4H (0.47) | LTA4HPOLBFKBP1AADRA1DADRA1A | |
| SCHEMBL8977442 | 0.82 | LTA4H (0.47) | LTA4HPOLBFKBP1AADRA1DADRA1A | |
| SCHEMBL12677313 | 0.82 | LTA4H (0.47) | LTA4HPOLBFKBP1AADRA1DADRA1A | |
| SCHEMBL4681706 | 0.82 | LTA4H (0.47) | LTA4HPOLBFKBP1AADRA1DADRA1A | |
| SCHEMBL7335555 | 0.81 | FKBP1A (0.47) | LTA4HPOLBFKBP1AADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL1374011 | 0.81 | PARP1 (0.42) | LTA4HPOLBPARP1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1374014 | 0.81 | PARP1 (0.42) | LTA4HPOLBPARP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9603819-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| EP-3048100-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | Novartis AG (CH) | 2016-07-27 | — | — | EP | disclosed |
| EP-2640375-B1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2016-05-18 | — | — | EP | disclosed |
| EP-2435402-B1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2016-04-13 | — | — | EP | disclosed |
| US-20150174089-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2015-06-25 | — | — | US | disclosed |
| US-9006249-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2015-04-14 | — | — | US | disclosed |
| US-8993631-B2 | Method of treating contrast-induced nephropathy | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20140336194-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2014-11-13 | — | — | US | disclosed |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | DERMIRA (CANADA), INC. (US) | 2014-04-17 | — | — | US | disclosed |
| EP-2640375-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | Novartis AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| US-8445694-B2 | Hydrazonopyrazole derivatives and their use as therapeutics | DERMIRA (CANADA), INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120252830-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2012-10-04 | — | — | US | disclosed |
| US-8263629-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| WO-2012065958-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Valocor Therapeutics, Inc. (CA) | 2011-09-29 | — | — | US | disclosed |
| US-7875728-B2 | tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death | Valocor Therapeutics, Inc. (CA) | 2011-01-25 | — | — | US | disclosed |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | DERMIRA (CANADA), INC. | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | LTA4H 1833/4885POLB 1521/4885FKBP1A 94/4885 |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | LTA4H 1833/4885POLB 1521/4885FKBP1A 94/4885 |
| US-20120252830-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | MME, GABRB1, GABRE | LTA4H 2258/4885POLB 3310/4885FKBP1A 1244/4885 |
| US-20150174089-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, GABRB1, GABRE | LTA4H 2258/4885POLB 3310/4885FKBP1A 1244/4885 |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | MKI67, CDK4, CCNC | LTA4H 3387/4885POLB 1409/4885FKBP1A 261/4885 |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | MME, GABRB1, GABRE | LTA4H 2258/4885POLB 3310/4885FKBP1A 1244/4885 |
| US-20140336194-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | LTA4H 737/4885POLB 3740/4885FKBP1A 3679/4885 |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | LTA4H 737/4885POLB 3740/4885FKBP1A 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.